SEC Form 10-Q filed by Day One Biopharmaceuticals Inc.
$DAWN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/9/2024 | $32.00 → $33.00 | Buy | Needham |
| 8/1/2024 | $11.00 → $24.00 | Underperform → Buy | BofA Securities |
| 4/24/2024 | $30.00 → $33.00 | Buy | Needham |
| 4/25/2023 | $34.00 → $9.00 | Buy → Underperform | BofA Securities |
| 2/8/2023 | $40.00 | Overweight | CapitalOne |
| 2/3/2023 | Perform | Oppenheimer | |
| 12/15/2022 | $35.00 | Buy | H.C. Wainwright |
| 12/14/2022 | $40.00 | Buy | Needham |
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $32.00 previously
BofA Securities upgraded Day One Biopharmaceuticals from Underperform to Buy and set a new price target of $24.00 from $11.00 previously
Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $30.00 previously
Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its third quarter 2024 financial results and highlighted recent corporate achievements. "Our third quarter results demonstrate continued patient demand
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30
Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7 Entered into exclusive licensing agreement with Ipsen to commercialize tovorafenib outside of the U.S. for approximately $111 million upfront in cash and equity investment at a premium Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million Company to host conference call and webcast today, July 30, 8:00 a.m. Eastern Time
8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
S-8 - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz
For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz
Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology
BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors. "We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Their deep expertise and leadership in oncology will further strengthen our Board and will be a great asset as we prepare for the potential launch of ou
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncology where he led its global oncology franchise. Day One co-founder Julie Grant, who served as board chair since 2021, will continue to serve as a member of the board of directors. "Garry is an accompl
SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
Preliminary 2024 OJEMDA™ (tovorafenib) net product revenue of approximately $57.2 million (unaudited) First dose cohort cleared in Phase 1a/b clinical trial of DAY301 (PTK7-targeted ADC) Ended 2024 with approximately $531.7 million in cash, cash equivalents and short-term investments (unaudited) Company to present at 43rd Annual J.P. Morgan Healthcare Conference today at 3:45 p.m. Pacific Time (6:45 p.m. Eastern Time) BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, to
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. A live audio webcast of the presentation will be available by visiting the Events & Presentations section of the Company's website at www.dayonebio.com. An archived replay of the webcast will be available for 30 days fo
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology